| Protocol |
Title |
Status |
Contact |
| 104063 |
KRT-232-115: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Versus Placebo Plus Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post PV MF), or Post Essential Thrombocythemia (post ET MF) That Have a Suboptimal Response to Ruxolitinib |
OPEN TO ACCRUAL |
 |
| 104120 |
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for low Tumor Burden Follicular Lymphoma |
OPEN TO ACCRUAL |
|
| 104131 |
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma: a Single Institution Phase II Trial |
OPEN TO ACCRUAL |
|
| 103991 |
M22-574: Phase 3 ABBV-383 vs Standard Available Treatment in Subjects with RRMM with at Least 2 Prior Lines of Therapies |
OPEN TO ACCRUAL |
|
| 104108 |
Phase 3 Study of Bomedemstat vs Best Available Therapy for 2L Essential Thrombocythemia |
OPEN TO ACCRUAL |
|
| 104054 |
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults with Selected Advanced Solid Tumors |
OPEN TO ACCRUAL |
|
| 103965 |
Refining Tamoxifen Dose for Premenopausal Breast Cancer Prevention (RENAISSANCE): A Phase II Single Arm Trial |
OPEN TO ACCRUAL |
|
| 104042 |
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer |
OPEN TO ACCRUAL |
|
| 104041 |
A Phase 3 Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared with Investigators Choice Monotherapy Treatment in Previously Treated Patients with Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma |
OPEN TO ACCRUAL |
|
| 104055 |
A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study) |
OPEN TO ACCRUAL |
|
| 103951 |
A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
OPEN TO ACCRUAL |
|
| 103976 |
A Phase 3, Randomized Study of CG0070 versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor |
OPEN TO ACCRUAL |
|
| 103982 |
Phase 3 Randomized Open-label Study of Adjuvant Pembrolizumab W/WO MK2870 in Resectable Stages II-IIIB(N2) NSCLC for Patients not Achieving pCR After Receiving Neoadjuvant Pembrolizumab with Platinum-Based Doublet Chemotherapy Followed by Surgery |
OPEN TO ACCRUAL |
|
| 103967 |
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination with Durvalumab compared With Durvalumab as Maintenance Therapy in Subjects with Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy with Platinum, Etoposide and Durvalumab |
OPEN TO ACCRUAL |
|
| 104000 |
A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma |
OPEN TO ACCRUAL |
|
| 104110 |
A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas |
OPEN TO ACCRUAL |
|
| 103779 |
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation |
OPEN TO ACCRUAL |
|
| 103816 |
Phase III, Open-label, Multicenter, Randomized Control Trial in Patients with r/r Mantle Cell Lymphoma to Evaluate the Efficacy, Safety and Pharmacokinetics of Glofitamab, a CD20xCD3 Bispecific Antibody |
OPEN TO ACCRUAL |
|
| 104009 |
A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physicians Choice in Third Line+ Advanced/Metastatic Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma |
OPEN TO ACCRUAL |
|
| 104007 |
A Phase 1b Dose Optimization Study of Sovilnesib (An Oral KIF18A Inhibitor) in Subjects with Advanced High Grade Serous Ovarian Cancer |
OPEN TO ACCRUAL |
|